Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Agenus ( (AGEN) ) has provided an update.
Agenus Inc. has secured a $22 million mortgage to bolster its cash reserves and support strategic operational realignment, focusing on its promising immunotherapy candidates, botensilimab and balstilimab, for colorectal cancer. The loan, facilitated by L&L Capital, involves a two-year term with interest payable in cash and stock. Agenus aims to significantly cut costs and transform its manufacturing operations while advancing its clinical programs, positioning itself for growth and innovation in cancer treatment.
Learn more about AGEN stock on TipRanks’ Stock Analysis page.
Trending Articles
- Long John Silver: Pirate, Mutineer, and Personal Finance Guru?
- ETH, ETHQ, ETHX: 3 Ethereum ETFs to Boost Portfolio Returns
- Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
